Netakimab - new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis

• Үндсэн зохиолчид: A. A. Kubanov (Зохиогч), A. L. Bakulev (Зохиогч), A. V. Samtsov (Зохиогч), V. R. Khairutdinov (Зохиогч), E. V. Sokolovskiy (Зохиогч), M. M. Kokhan (Зохиогч), A. V. Artemyeva (Зохиогч), E V. Chernyaeva (Зохиогч), R. A. Ivanov (Зохиогч)
• Формат: Ном
• Хэвлэсэн: State Scientific Center of Dermatovenereology and Cosmetology, 2019-07-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Netakimab, the original monoclonal antibody against IL-17A, is an innovative drug for the treatment of moderate-to-severe plaque psoriasis in patients who have indications for systemic therapy or phototherapy. Netakimab was approved in Russian Federation, registration certificate number ЛП-005439 fr...